Darolutamide: all 76 studies that test it
Page 1 of 1. Open to participants first (34), then studies with results posted, then the rest; newest registration first within each.
- Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate CancerNot yet recruitingNCT07852195Phase 2/3
- Efficacy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer.Not yet recruitingNCT07730151Phase 2
- Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate CancerNot yet recruitingNCT07717099Phase 2
- Prostate Androgen Response Investigation Using a Stratification BIOmarker; Predicting Prostate Cancer Downstaging by Neoadjuvant Darolutamide With PCAI ImmunoScoreRecruitingNCT07617272Phase 2
- Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoadjuvant Treatment of High-Risk Prostate Cancer: A Multicenter Prospective, Single-Arm Clinical StudyNot yet recruitingNCT07516704Early Phase 1
- A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.RecruitingNCT07450599Phase 2
- Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019Not yet recruitingNCT07282197Phase 2
- A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)RecruitingNCT07244341Phase 1
- TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)RecruitingNCT07190300Phase 1/2
- Supraphysiologic Testosterone Priming Induces Darolutamide Extended ResponseRecruitingNCT07142551Phase 2
- A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)RecruitingNCT07103018Phase 1
- Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate CancerRecruitingNCT07027124Phase 2
- Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBCRecruitingNCT07016399Phase 2
- A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPCRecruitingNCT06785636Phase 1/2
- Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.Not yet recruitingNCT06660862Phase 4
- Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate CancerRecruitingNCT06631521Phase 1
- Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of RelapseRecruitingNCT06625970Phase 3
- Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate CancerRecruitingNCT06575257Phase 2
- Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)RecruitingNCT06401980Phase 2
- Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular TracersRecruitingNCT06282588Phase 2/3
- SNV1521 in Participants With Advanced Solid TumorsRecruitingNCT06220864Phase 1
- Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate CancerRecruitingNCT06190899Phase 1/2
- Intermittent Darolutamide Treatment in the Triple Therapy of mHSPCRecruitingNCT06177015Phase 3
- Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate CancerRecruitingNCT06173362Phase 2
- A Phase II Neoadjuvant Study of Darolutamide Plus ADT in Men With Localized Prostate CancerRecruitingNCT06029036Phase 2
- A Phase 2 Trial of Darolutamide as a Prostate-Specific Membrane Antigen (PSMA) Expression Enhancer in Patients With Localized Prostate CancerRecruitingNCT05900973Phase 2
- Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPCRecruitingNCT05762536Phase 2
- A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)RecruitingNCT05348876Phase 4
- Efficacy and Safety of Darolutamide Combined With ADT in High-risk/Very High-risk Localized Prostate CancerRecruitingNCT05249712Phase 2
- Evaluation of dAroLutamide Addition to anDrogen Deprivation Therapy and radIatioN Therapy in Newly Diagnosed Prostate Cancer With Pelvic Lymph Nodes MetastasesRecruitingNCT05116475Phase 3
- ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)RecruitingNCT04916613Phase 3
- Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate CancerRecruitingNCT04641078Phase 2
- Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate CancerNot yet recruitingNCT04176081Phase 2
- ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerRecruitingNCT03903835Phase 3
- A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With EnzalutamideCompletedNCT05526248Phase 2Results posted
- A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.CompletedNCT05059236Phase 2Results posted
- Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate CancerTerminatedNCT04737109Phase 1/2Results posted
- Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate CancerCompletedNCT04736199Phase 3Results posted
- Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or EnzalutamideCompletedNCT04335682Phase 2Results posted
- A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC PatientsTerminatedNCT04237584Phase 3Results posted
- Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)TerminatedNCT04157088Phase 2Results posted
- A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of DarolutamideCompletedNCT03004534Early Phase 1Results posted
- Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate CancerCompletedNCT02799602Phase 3Results posted
- Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate CancerCompletedNCT02200614Phase 3Results posted
- Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001CompletedNCT01429064Phase 2Results posted
- Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate CancerCompletedNCT01317641Phase 1/2Results posted
- COACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcerActive, not recruitingNCT06627530Phase 4
- Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)Active, not recruitingNCT06463457Phase 2
- Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell TumorsActive, not recruitingNCT06169124Phase 2
- Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial TreatmentTerminatedNCT05999968Phase 1
- A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.CompletedNCT05938270Phase 1
- A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local TherapiesActive, not recruitingNCT05794906Phase 3
- Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland CancersActive, not recruitingNCT05669664Phase 2
- Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance TrialActive, not recruitingNCT05050084Phase 3
- Psma Intensity Can be Altered by Androgen and Phospho-SrC ObstructionCompletedNCT04925648Phase 2
- Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial)CompletedNCT04558866Phase 2
- Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE StudyActive, not recruitingNCT04484818Phase 3
- Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by BayerActive, not recruitingNCT04464226Phase 3
- Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the ProstateActive, not recruitingNCT04136353Phase 3
- Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)Active, not recruitingNCT04070209Phase 2
- INTREPId (INTermediate Risk Erection PreservatIon Trial)Active, not recruitingNCT04025372Phase 2
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate CancerCompletedNCT03724747Phase 1
- Imaging Study to Compare Effects of Darolutamide and Enzalutamide With Respect to Placebo on the Blood Flow in the Brain in Healthy Male Volunteers.CompletedNCT03704519Phase 1
- Prostate Cancer Biomarker Enrichment and Treatment SelectionActive, not recruitingNCT03385655Phase 2
- Study on Androgen Receptor and Triple Negative Breast CancerCompletedNCT03383679Phase 2
- A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate CancerCompletedNCT03314324Phase 2
- Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates of CYP3A4 and P-gp in Healthy Male VolunteersCompletedNCT03237416Phase 1
- Drug-drug Interaction (DDI) Study to Assess ODM-201 as a Victim of CYP3A4 Inhibition or InductionCompletedNCT03048110Phase 1
- ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate CancerActive, not recruitingNCT02972060Phase 2
- ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.TerminatedNCT02933801Phase 2
- Effect of Hepatic and Renal Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1841788 (ODM-201)CompletedNCT02894385Phase 1
- Drug-drug Interaction Study Using Rosuvastatin as a Breast Cancer Resistant Protein (Efflux Transporter), Organic Anion-transporting Polypeptide (OATP)1B1, and OATP1B3 (Uptake Transporters) Probe SubstrateCompletedNCT02671097Phase 1
- Mass Balance, Pharmacokinetics, Biotransformation and Bioavailability Study of ODM-201 in Healthy Male SubjectsCompletedNCT02418650Phase 1
- Phase 1 Dose Escalation Study of BAY 1841788 in Japanese Metastatic Castration-resistant Prostate Cancer (mCRPC) SubjectsCompletedNCT02363855Phase 1
- Bioavailability Study of ODM-201 in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate CancerCompletedNCT01784757Phase 1